Impact of the components of metabolic syndrome on survival in a group of hemodialysis

##plugins.themes.academic_pro.article.sidebar##

Published Jan 27, 2016
Download
pdf
Vol. 93 No. 12 (2015): Issue Dec 2015

##plugins.themes.academic_pro.article.main##

Imen Gorsane
Madiha Mahfoudhi
Fathi Younsi
Samia Barbouch
Taieb Ben Abdallah

Abstract

SUMMARY
Background: Metabolic syndrome is defined by the combination of high blood pressure, dyslipidemia, central obesity and a state of insulin resistance. Its prevalence is high in hemodialysis.
Aim : The aim of this work is to see the impact of metabolic syndrome on mortality and morbidity in our hemodialysis patients.
Methods : This is a retrospective study of 120 chronic hemodialysis patients. The metabolic syndrome was investigated according to the criteria of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). Survival was estimated based on each parameter of the metabolic syndrome. A comparison by sex was performed for the following parameters: age, diabetes, hypertension, obesity, waist circumference, dyslipidemia, coronary artery disease and heart failure.
Results : Forty chronic hemodialysis patients with metabolic syndrome have been the subject of this study. The mean age was 55.97 years and the sex ratio was 1.88. Seventy percent had diabetes and 90% were hypertensive. Coronary artery disease was present in 57.5% of cases of heart failure in 52.5% of cases. There was no significant difference in 10 years survival depending on the presence of each component of the metabolic syndrome. The study by sex showed no significant difference except for hyper LDL cholesterol.
Conclusion : Our study showed no impact of the components of metabolic syndrome on survival. There is a high prevalence of cardiovascular complications but causality with the metabolic syndrome could not be demonstrated.

Keywords:

Metabolic syndrome, Renal dialysis, Cardiovascular events, Morbidity, Mortality.

##plugins.themes.academic_pro.article.details##

References

  1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
  2. Prasad GV. Metabolic syndrome and chronic kidney disease: Current status and future directions. World J Nephrol 2014;3:210-9.
  3. Kubrusly M, Oliveira CM, Simões PS et al. Prevalence of metabolic syndrome according to NCEP-ATP III and IDF criteria in patients on hemodialysis. J Bras Nefrol 2015;37:72-8
  4. Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Ilic M, Stokić E. Metabolic syndrome in HD patients: association with body composition, nutritional status, inflammation and serum iron. Intern Med 2007;46: 945-51.
  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285 : 2486-97.
  6. Amihăesei IC, Chelaru L. Metabolic syndrome a widespread threatening condition; risk factors, diagnostic criteria, therapeutic options, prevention and controversies: an overview. Rev Med Chir Soc Med Nat Iasi 2014;118:896-900.
  7. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21-8.
  8. Bakker SJ, Gansevoort RT, Zeeuw DD. Metabolic syndrome: a fatamorgana? Nephro Dial Transplant 2007;22:15-20.
  9. Isomaa B, Almgren P, Tuomi T et al. Cardiovascula rmorbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24 : 683-9.
  10. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288 : 2709-16.
  11. Chen HH, Wu CJ, Chen YC, Tsai CS, Lin FJ, Yeh HI . Metabolic syndrome is associated with severe coronary artery disease and poor cardiac outcome in end- stage renal disease patients with acute coronary syndrome. Coron Artery Dis 2006; 17: 593-6.
  12. Yang SY, Chiang CK, Hsu SP et al. Metabolic syndrome predicts hospitalization in hemodialysis patients: a prospective Asian cohort study. Blood Purif 2007; 25: 252-9.
  13. Shahrokh S, Heydarian P, Ahmadi F, Saddadi F, Razeghi E. Association of inflammatory biomarkers with metabolic syndrome in hemodialysis patients. Ren Fail 2012;34:1109-13.
  14. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992; 41: 715-22.
  15. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-78.
  16. Park JT, Chang TI, Kim DK et al. Metabolic syndrome predicts mortality in non-diabetic patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2010; 25: 599-604.
  17. Tu SF, Chou YC, Sun CA, Hsueh SC, Yang T. The prevalence of metabolic syndrome and factors associated with quality of dialysis among hemodialysis patients in Southern Taiwan. Glob J Health Sci 2012;4:53-62.
  18. Wu CC, Liou HH, Su PF et al. Abdominal obesityis the most significant metabolic syndrome component predictive of cardiovascular events in chronic hemodialysis patients. Nephrol Dial Transplant 2011;26:3689- 95.
  19. Frohlich M, Imhof A, Berg G et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23:1835-9.
  20. Jofre R, Rodriguez-Benitez P, Lopez-Gomez JM, Pérez-Garcia R. Inflammatory syndrome in patients on hemodialysis. J Am Soc Nephrol 2006; 17: S274-80.
  21. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events :an 8- year follow-up of 14 719 initially healthy American women. Circulation 2003 ; 107 : 391-7.
  22. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63: 793-808.
  23. Al Saran K, Elsayed S, Sabry A, Hamada M. Obesity and metabolic syndrome in hemodialysis patients: single center experience. Saudi J Kidney Dis Transpl 2011;22:1193-8.
  24. Xie Q, Zhang AH, Chen SY et al. Metabolic syndrome isassociated with better nutritional status, but not with cardiovascular disease or allcause mortality in patients on haemodialysis. Arch Cardiovasc Dis 2012;105:211-7.
  25. Stolic RV, Trajkovic GZ, Peric VM et al. Impact of metabolic syndrome and malnutrition on mortality in chronic hemodialysis patients. J RenNutr 2010;20:38-43.
  26. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-7.
  27. Matsuzawa Y. Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006;3:35-42.
  28. Wang J, Li H, Franco OH, Yu Z, Liu Y, Lin X. Adiponectin and metabolic syndrome in middle-aged and elderly Chinese. Obesity (Silver Spring) 2008;16:172-8.
  29. Tsai JP, Tsai CC, Liu HM, Lee CJ, Liou HH, Hsu BG. Hyperleptinaemia positively correlated with metabolic syndrome in hemodialysis patients. Eur J Intern Med 2011;22:e105-9.
  30. Tsai JP, Liou HH, Liu HM, Lee CJ, Lee RP, Hsu BG. Fasting serum fatty acid-binding protein 4 level positively correlates with metabolic syndrome in hemodialysis patients. Arch Med Res 2010;41:536-40.